🏛️ Verified NIH Record • Updated 2026-08-26

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency (NCT06462547)

The ADAPT Study: An Open-label, Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Inozyme Pharma

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.

Who can join: Review the eligibility criteria below.

Location: Mayo Clinic — Rochester, Minnesota

Age range: 1 Year

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (5 Sites)

  • Mayo Clinic — Rochester, Minnesota
  • Clinilabs Drug Development Corporation — Eatontown, New Jersey
  • Necker-Enfants Malades Hospital — Paris,
  • Universitätsklinikum Hamburg-Eppendorf (UKE) — Hamburg,
  • Medical Research Network Ltd. — Milton Keynes,

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
  • 💵 Compensation indicated: The study will consist of a 30-day Screening Period, followed by an open-label Treatment Period during which all participants will receive once-weekly subcutaneous (SC) doses of INZ-701 and continu...

Explore by condition: All Gene Mutations clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗